These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38493669)
1. Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH). Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q Atherosclerosis; 2024 Apr; 391():117471. PubMed ID: 38493669 [TBL] [Abstract][Full Text] [Related]
2. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344 [TBL] [Abstract][Full Text] [Related]
3. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172 [TBL] [Abstract][Full Text] [Related]
4. Effect of moderate-intensity statin on carotid intraplaque neovascularization of coronary artery disease: a retrospective cohort study. Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q Quant Imaging Med Surg; 2024 Feb; 14(2):1660-1672. PubMed ID: 38415148 [TBL] [Abstract][Full Text] [Related]
5. Effect of Evolocumab on Coronary Plaque Composition. Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824 [TBL] [Abstract][Full Text] [Related]
6. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study). Wang YW; Xu J; Ma L; Hu H; Chen HW; Hua JS; Kong XY; Li D; Li LW; Pan JY; Wu J BMJ Open; 2024 Jul; 14(7):e083730. PubMed ID: 39009458 [TBL] [Abstract][Full Text] [Related]
8. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. Räber L; Ueki Y; Otsuka T; Losdat S; Häner JD; Lonborg J; Fahrni G; Iglesias JF; van Geuns RJ; Ondracek AS; Radu Juul Jensen MD; Zanchin C; Stortecky S; Spirk D; Siontis GCM; Saleh L; Matter CM; Daemen J; Mach F; Heg D; Windecker S; Engstrøm T; Lang IM; Koskinas KC; JAMA; 2022 May; 327(18):1771-1781. PubMed ID: 35368058 [TBL] [Abstract][Full Text] [Related]
9. Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review. Cui E; Kersche G; Grubic N; Hétu MF; Pang SC; Sillesen H; Johri AM J Clin Lipidol; 2023; 17(3):315-326. PubMed ID: 37173161 [TBL] [Abstract][Full Text] [Related]
10. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome. Hao Y; Yang YL; Wang YC; Li J Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153 [TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276 [TBL] [Abstract][Full Text] [Related]
12. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR; N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome. Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364 [TBL] [Abstract][Full Text] [Related]
14. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China. Liu Y; Han B Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Rosenson RS; Daviglus ML; Handelsman Y; Pozzilli P; Bays H; Monsalvo ML; Elliott-Davey M; Somaratne R; Reaven P Diabetologia; 2019 Jun; 62(6):948-958. PubMed ID: 30953107 [TBL] [Abstract][Full Text] [Related]
17. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224 [TBL] [Abstract][Full Text] [Related]
18. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. Yano H; Horinaka S; Ishimitsu T J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA; JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291 [TBL] [Abstract][Full Text] [Related]